Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 148-155 , April 2002

111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial

  • Irene Virgolini

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • Corresponding Author InformationAddress reprint requests to Irene Virgolini, MD, Institute of Nuclear Medicine, Lainz Hospital, City of Vienna, Wolkersbergenstrasse 1, A-1130 Vienna, Austria
    • ,
  • Keith Britton

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • John Buscombe

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • Roy Moncayo

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • Giovanni Paganelli

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • Pietro Riva

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy

References 

  1. Brazeau P, Vale W, Burgus R, et al. Hypo-thalamic polypeptide that inhibits the secretion of im-munoreactive pituitary growth hormone. Science. 1973;179:77–79
  2. Aguila Rodriguez AM, Aguila-Mansilla HN, Lee WT. Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture. Endocrinology. 1996;137:1585–1590
  3. Karalis K, Mastorakos G, Chrousos GP, et al. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest. 1994;93:2000–2006
  4. Yamada Y, Post SR, Wang K, et al. Cloning and functional characterization of family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. In: Proc Natl Acad Sci USA. 89:1992;p. 251–255
  5. Yamada Y, Reisine T, Law SF, et al. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol. 1992;6:2136–2142
  6. Yasuda K, Rens-Domiano S, Breder CD, et al. Cloning of a somatostatin receptor, SSTR3, coupled to adenylylcyclase. J Biol Chem. 1992;267:20422–20428
  7. Demchyschyn LL, Srikant CB, Sunahara RK, et al. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol Pharmacol. 1993;43:894–901
  8. Corness JD, Demchyschyn LL, Seeman P, et al. A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 1993;321:279–284
  9. Rohrer L, Raulf F, Bruns C, et al. Cloning and characterization of a fourth human somatostatin receptor. In: Proc Natl Acad Sci USA. 90:1993;p. 4196–4200
  10. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Meds. 1996;334:246–254
  11. Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994;54:690–700
  12. Krenning EP, Bakker WH, Breeman WA, et al. Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–244
  13. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide in man: Metabolism, dosimetry and comparison with [123I-Tyr-3-]-octreotide. J Nucl Med. 1992;33:652–658
  14. Smith-Jones P, Bischof C, Leimer M, et al. Indium-111-DOTA-lanreotide: A novel tumor diagnostic and therapeutic somatostatin analog. Endocrinology. 1999;140:5138–5148
  15. Krenning EP, Bakker WH, Kwekkeboom DJ, et al. Biodistribution of a new chelated somatostatin analogue, [In-111-DOTA-D-Phe1-Tyr3]-octreotide; comparison with [In-111-DTPA-D-Phe-1]-octreotide in humans. J Nucl Med. 1997;38:103(A)
  16. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labeled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–418
  17. Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose tumor patients. J Nucl Med. 1998;39:1928–1936
  18. Leimer M, Kurtaran A, Smith-Jones P, et al. Response to treatment with 90Y-DOTA-lanreotide of a patient with metastaticgastrinoma. J Nucl Med. 1998;39:2090–2094
  19. Virgolini I, Traub T, Novotny C, et al. New trends in peptide receptor radioligands. Q J Nucl Med. 2001;45:153–159
  20. Virgolini I, Smith-Jones P, Moncayo R, et al. 111In/90Y-DOTA-lanreotide scintigraphy and therapy: Initial clinical results of “MAURITIUS.”. Eur J Nucl Med. 1998;25:884
  21. Moncayo R, Riccabona G, Wenger M, et al. Clinical utility of 90Y-DOTA-lanreotide in the treatment of anaplastic or metastatic undifferentiated thyroid carcinoma. Eur J Nucl Med. 2000;26:1156
  22. Buscombe R, Caplin ME, Hepplewhite J, et al. Use of radiolanreotide to treat somatostatin receptor positive tumors. Eur J Nucl Med. 2001;28:1198
  23. Goldsmith SJ, Kostakoglu L, Smith-Jones PM, et al. Treatment of somatostatin receptor (SSTR) positive tumors with Y-90-DOTA-lenreotide: Preliminary studies. J Nucl Med. 2001;41:267
  24. De Nardo SJ. Tumor-targeted radionuclide therapy trial design driven by patient dosimetry. J Nucl Med. 2000;41:104–105
  25. Dorr U, Wurm K, Hornig E, et al. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. Horm Metab Res Suppl. 1993;27:36–43
  26. Soresi E, Invernizzi G, Boffi R, et al. Intensification of 111In-DTPA-octreotide scintigraphy by means of pretreatment with cold octreotide in small cell lung cancer. Lung Cancer. 1997;17:231–238
  27. Morgensen CE, Solling . Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest. 1977;37:477–486
  28. abstr Konijnenberg MW. Dose-effect relation for kidney damage after 90Y-DOTA-octreotide therapy. J Nucl Med. 2000;41(suppl):236
  29. De Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of Indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388–1392
  30. Hammond PJ, Wade AF, Gwilliam ME, et al. Aminoacid infusion blocks renal tubular uptake of an indium-labeled somatostatin analog. Br J Cancer. 1993;67:1437–1439
  31. Akizawa H, Arano Y, Uezono T, et al. Renal metabolism of 111In-DTPA-D-Phel-octreotide in vivo. Bioconjug Chem. 1998;9:662–670
  32. Krenning EP, Kooij PP, Pauwels S, et al. Somatostatin receptor: Scintigraphy and radionuclide therapy. Digestion. 1996;57(suppl):57–61
  33. Tiennsuu Janson E, Eriksson B, Oberg K, et al. Treatment with high dose [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors-evaluation and toxic effects. Acta Oncol. 1999;38:373–377
  34. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In pentreotide. State of the art and perspectives. Q J Nucl Med. 2000;44:88–95
  35. Buscombe JR, Caplin ME, Croasdale PL, et al. Targeted treatment of disseminated NETs with radiopeptides. J Nucl Med. 2001;41:267
  36. deJong M, Bernard BF, deBruin J, et al. Internalisation of radiolabeled DTPA-octreotide and DOTA-tyr3-octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 1998;19:283–288
  37. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med. 1999;26:1439–1447
  38. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nuc Med. 2001;28:426–434
  39. Smith MC, Liu J, Chen T, et al. OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion. 2000;62(suppl 1):69–72
  40. Waldherr C, Maecke HR, Haldemann A, et al. Clinical value of 90Y-DOTA-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) of neuroendocrine tumor tissue: First phase II study. J Nucl Med. 2000;41(suppl):146
  41. Traub T, Andreae F, Angelberger P, et al. Experimental radiopeptide therapy (ERT) with 90Y-DOTA-D-Phe1-Tyr3-octreotide. J Nucl Med. 2000;41:146
  42. Valkeman R, Jamar F, Jonard P, et al. Targeted radiotherapy with 90Y-DOTA-Tyr3-octreotide (90Y-SMT487; OCTREOTHER®): A phase I study. J Nucl Med. 2000;41:111
  43. De Jong M, Breeman WA, Bernard BF, et al. Tumour uptake of the radiolabelled somatostatin analogue (DOTA-Tyr3) octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693–698
  44. (abstr) De Jong M, Breeman WA, Bernard HF, et al. Response to radionuclide therapy using 90Y- and 111In-labeled somatosta-tin analogs is dependent on tumor size. J Nucl Med. 2000;41:147
  45. Cremonesi N, Ferrari M, Zoboli S, et al. Biokinetics and dosimetry in patients administered with In-111-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with Y-90-DOTATOC. Eur J Nucl Med. 1999;26:877–886
  46. De Jong M, Breeman WA, Bernard HF, et al. [DOTA, Tyr3]octreotate, labeled with 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors. J Nucl Med. 2000;41:111
  47. Kweekeboom DJ, Bakker WH, Kooij PP, et al. 111In-DTPA-Tyr3-octreotate: Comparison with 111In-DTPA-octreotide in patients. J Nucl Med. 2000;41:31
  48. Weetman A. Graves' disease. N Engl J Med. 2000;343:17

1 Supported in part by the Austrian National Bank, Anniversary Foundation Projects 7556 and 8320, as well as by an Anniversary Foundation of the Mayor of the City of Vienna.

PII: S0001-2998(02)80033-2

doi: 10.1053/snuc.2002.31565

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 148-155 , April 2002

Article Tools